Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

4.490 -0.320 (-6.65%)

Streaming Delayed Price Updated: 2:03 PM EDT, Mar 30, 2026 Add to My Watchlist

Price and Volume

Volume	866,654
Open	4.800
Bid (Size)	4.480 (1,000)
Ask (Size)	4.490 (500)
Prev. Close	4.810
Today's Range	4.475 - 4.800
52wk Range	4.250 - 7.250
Shares Outstanding	28,919,810
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

March 17, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

March 12, 2026

From Candel Therapeutics

Via GlobeNewswire

Performance

YTD	-17.5%	-17.5%
1 Month	-14.5%	-14.5%
3 Month	-22.6%	-22.6%
6 Month	-16.9%	-16.9%
1 Year	-20.5%	-20.5%

More News

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

March 09, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗

October 14, 2025

Via Stocktwits

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

February 24, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Pricing of Public Offering

February 19, 2026

From Candel Therapeutics

Via GlobeNewswire

Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today ↗

February 19, 2026

Via Stocktwits

Candel Therapeutics Announces Proposed $100 Million Public Offering

February 19, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

February 19, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

February 11, 2026

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2026

From Candel Therapeutics

Via GlobeNewswire

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗

December 05, 2025

Via Stocktwits

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

November 17, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 13, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

November 04, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

November 03, 2025

From Candel Therapeutics

Via GlobeNewswire

EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗

October 23, 2025

Via Benzinga

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

October 16, 2025

From Candel Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 14, 2025

Via Benzinga

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

October 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

October 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

October 03, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 29, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 17, 2025

From Candel Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?

Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Candel Therapeutics, Inc. - Common Stock trade on?

Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?

The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market

What is the current price of Candel Therapeutics, Inc. - Common Stock?

The current price of Candel Therapeutics, Inc. - Common Stock is 4.490

When was Candel Therapeutics, Inc. - Common Stock last traded?

The last trade of Candel Therapeutics, Inc. - Common Stock was at 03/30/26 02:03 PM ET

What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?

The market capitalization of Candel Therapeutics, Inc. - Common Stock is 129.85M

How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?

Candel Therapeutics, Inc. - Common Stock has 130M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.